Organization | University of Central Lancashire

University of Central Lancashire Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Preston United States (1828)

Organization Overview

First Clinical Trial

2016

NCT02613494

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Jonathan Sinclair | University of Central Lancashire | University of Central Lancashire, Burnley, UK

Active Ingredients

Drugs in Phase 4 Trials (5)

beclomethasone (vanceril) (1 trial)

fluticasone (cutivate) (1 trial)

formoterol (foradil) (1 trial)

glycopyrronium (robinul) (2 trials)

vilanterol (Anoro Elipta) (1 trial)

Drugs in Phase 2 Trials (1)

scopolamine (transderm scop) (1 trial)

Drugs in Other Trials (5)

bifidobacterium lactis (1 trial)

cherry (2 trials)

collagen (1 trial)

Lactobacillus acidophilus (1 trial)

peppermint extract (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Sialorrhea (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 11